Patents by Inventor Gary W. Zlotnick
Gary W. Zlotnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8101194Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: October 11, 2002Date of Patent: January 24, 2012Assignee: Wyeth LLCInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20110076299Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: March 20, 2009Publication date: March 31, 2011Applicant: WYETH HOLDINGS CORPORATIONInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7785608Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: September 2, 2003Date of Patent: August 31, 2010Assignee: Wyeth Holdings CorporationInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7666626Abstract: A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.Type: GrantFiled: December 17, 2008Date of Patent: February 23, 2010Assignees: Wyeth Holdings Corporation, The Curators of the University of MissouriInventors: Bruce A. Green, Gary W. Zlotnick, Leah D. Fletcher, Arnold L. Smith, Thomas J. Reilly
-
Patent number: 7615229Abstract: A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.Type: GrantFiled: March 13, 2003Date of Patent: November 10, 2009Assignees: Wyeth Holdings Corporation, The Curators of the University of MissouriInventors: Bruce A. Green, Gary W. Zlotnick, Leah D. Fletcher, Arnold L. Smith, Thomas J. Reilly
-
Publication number: 20090202593Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: June 16, 2008Publication date: August 13, 2009Applicant: WyethInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20090148465Abstract: A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.Type: ApplicationFiled: December 17, 2008Publication date: June 11, 2009Applicants: Wyeth Holdings Corporation, The Curators of the University of MissouriInventors: Bruce A. Green, Gary W. Zlotnick, Leah D. Fletcher, Arnold L. Smith, Thomas J. Reilly
-
Patent number: 6921537Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.Type: GrantFiled: March 5, 2002Date of Patent: July 26, 2005Assignee: WyethInventor: Gary W. Zlotnick
-
Publication number: 20040167068Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: September 2, 2003Publication date: August 26, 2004Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Publication number: 20020136741Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.Type: ApplicationFiled: March 5, 2002Publication date: September 26, 2002Applicant: American Cyanamid CompanyInventor: Gary W. Zlotnick
-
Patent number: 6420134Abstract: Protein “e” of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein “e” and peptides or proteins having a shared epitope, can be used to vaccinate against non-typable (and typable) H. influenzae and to prevent otitis media caused by H. influenzae. For this purpose, protein “e” or derivatives thereof can be produced in native, synthetic or recombinant forms and can be administered alone or in conjunction with other antigens of H. influenzae. Protein “e” can also be used in multivalent vaccines designed for H. influenzae and one or more other infectious organisms.Type: GrantFiled: May 23, 1995Date of Patent: July 16, 2002Assignee: Praxis Biologics, Inc.Inventors: Bruce A. Green, Gary W. Zlotnick
-
Patent number: 6355253Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.Type: GrantFiled: June 6, 1995Date of Patent: March 12, 2002Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick
-
Patent number: 5955580Abstract: Protein "e" of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein "e" and peptides or proteins having a shared epitope, can be used to vaccinate against nontypable (and typable) H. influenzae and to prevent otitis media caused by H. influenzae. For this purpose, protein "e" or derivatives thereof can be produced in native, synthetic or recombinant forms and can be administered alone or in conjunction with other antigens of H. influenzae. Protein "e" can also be used in multivalent vaccines designed for H. influenzae and one or more other infectious organisms.Type: GrantFiled: May 23, 1995Date of Patent: September 21, 1999Assignee: Praxis Biologies, Inc.Inventors: Bruce A. Green, Gary W. Zlotnick
-
Patent number: 5780601Abstract: "A method of purifying protein "e" from Haemophilus influenzae includes disrupting H. influenzae cells, subjecting the disrupted cells by differential sedimentation to obtain a total cell membrane fraction, fractionating the total cell membrane into inner and outer membrane components by density gradient sedimentation or by differential solubilization of the inner membrane component with detergents, obtaining a subfraction of the preparation of the outer membrane components which is enriched in protein "e" by extraction with an aqueous solution of 0.1-2.0% N-lauroyl sarcosine, sodium salt, solubilizing the protein "e" from the subfraction by a two-step differential solubilization process with sulfobetaine detergents, and recovering the aqueous solution which contains the purified protein "e".Type: GrantFiled: May 23, 1995Date of Patent: July 14, 1998Assignee: Praxis Biologics, Inc.Inventors: Bruce A. Green, Gary W. Zlotnick
-
Patent number: 5770213Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: May 5, 1994Date of Patent: June 23, 1998Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick
-
Patent number: 5601831Abstract: Protein "e" of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein "e" and peptides or proteins having a shared epitope, can be used to vaccinate against non-typable (and typable) H. influenzae and to prevent otitis media caused by H. influenzae. For this purpose, protein "e" or derivatives thereof can be produced in native, synthetic or recombinant forms and can be administered alone or in conjunction with other antigens of H. influenzae. Protein "e" can also be used in multivalent vaccines designed for H. influenzae and one or more other infectious organisms.Type: GrantFiled: March 9, 1990Date of Patent: February 11, 1997Assignee: Praxis Biologics, Inc.Inventors: Bruce A. Green, Gary W. Zlotnick
-
Patent number: 5196338Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.Type: GrantFiled: February 15, 1990Date of Patent: March 23, 1993Assignee: Praxis Biologics, Inc.Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: 5108744Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods includng novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequence encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization.Type: GrantFiled: November 9, 1989Date of Patent: April 28, 1992Assignee: Praxis Biologics, Inc.Inventors: Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: 5098997Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.Type: GrantFiled: September 1, 1988Date of Patent: March 24, 1992Assignee: Praxis Biologics, Inc.Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: RE37741Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: June 21, 2000Date of Patent: June 11, 2002Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick